This paper is only available as a PDF. To read, Please Download here.
A group of 14 patients with 16 composite bypassing grafts composed of synthetic crimped Teflon and autogenous vein have been followed postoperatively to either thrombosis of the graft or for as long as 14 months of patency. The expected usefulness of this method is not borne out by this analysis in which 13 of the 16 grafts had relatively early occlusion, although patency was established throughout the immediate postoperative period. This high incidence of failure leads to pessimism regarding usefulness of the composite graft for future patients. Experience outside this series indicates that long autogenous vein grafts with or without proximal thromboendarterectomy are superior to composite grafts.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Autogenous vein grafts and related aspects of peripheral arterial disease.Charles C Thomas, Publisher, Springfield, Ill1959
- Failure of homografts as arterial replacements.Surgery. 1959; 46: 565
- Late occlusion of femoral and popliteal fabric arterial grafts.Surg. Gynec. & Obst. 1960; 110: 714
- Late behavior of vascular substitutes.Ann. Surg. 1960; 151: 867
- Autogenous saphenous vein bypass grafts in femoropopliteal obliterative arterial disease.Surgery. 1962; 51: 62
Pridgen, W. R., and Dale, W. A.: Composite (crimped Teflon and autogenous vein) grafts in small canine arteries, Am. Surgeon. In press.
- Biologic fate of human arterial homografts.A. M. A. Arch Surg. 1957; 75: 506
Received: October 3, 1961
© 1962 Published by Elsevier Inc.